?
Optimal patient populations**: Which patients are most likely to benefit?
active
open question
Created: 2026-04-25T20:28:44
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-86433e43-da18-43dd-9073-7e
Open Question
open
Wiki: therapeutics-glp-1-receptor-agonists-neurodegeneration
Optimal patient populations**: Which patients are most likely to benefit?
Importance Elo
1500
Field Rank
Rank #988 in therapeutics
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page therapeutics-glp-1-receptor-agonists-neurodegeneration
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:28:44.725336'} |
| field_tag | therapeutics |
| source_id | therapeutics-glp-1-receptor-agonists-neurodegeneration |
| sub_field | glp-1-receptor-agonists-neurodegeneration |
| source_kind | wiki |
| question_hash | 0a73f63e2022e20836c4b8cc913a5e1e9266d91a1b4dcac86272fc3722c2459e |
| question_text | Optimal patient populations**: Which patients are most likely to benefit? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page therapeutics-glp-1-receptor-agonists-neurodegeneration |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.